CClinicalTrials.gg
Sign In
CompletedNCT01306110DIABSCANUpdated Jan 8, 2016

Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study

An observational study in Diabetes, sponsored by Association HGE CHU Bordeaux Sud. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-08.

Sponsored by Association HGE CHU Bordeaux Sud · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
277
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.

Read the detailed description

Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this large population needs non-invasive methods. Recently, FibroScan was shown to be a good method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient elastography (FibroScan) in patients with diabetes.

02

Conditions studied

  • Diabetes

Keywords

  • Liver fibrosis
  • diabetes
  • Fibroscan
  • Fibrotest
  • noninvasive fibrosis biomarkers
03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's enrollment of 277 is above the median of 151 across 587 observational studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Association HGE CHU Bordeaux Sud is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diabetes

Inclusion criteria

  • Male or female subjects
  • More than 18 years of age
  • Patients with Diabetes
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients refusing to participate to the study and to provide written informed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
277 participants (actual)
06

Study locations

1 site
  • Service Hepato-Gastroentérologie Hopital Haut-Leveque
    Pessac, 33604, France
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01306110
Lead sponsor
Association HGE CHU Bordeaux Sud
Responsible party
de Ledinghen (Professor, Association HGE CHU Bordeaux Sud) — Principal investigator
First posted
Mar 1, 2011
Start date
Jun 2007
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Jan 8, 2016

Study contacts

Victor De Ledinghen, MD PhD
study director · University Hospital, Bordeaux
Juliette Foucher, MD
principal investigator · University Hospital, Bordeaux
Julien Vergniol, MD
principal investigator · University Hospital, Bordeaux
Vincent Rigalleau, MD PhD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Cirrhosis→

Other studies from this sponsor

Association HGE CHU Bordeaux Sud

Start the discussion